Navigation Links
Oncolytics Biotech Inc. Announces 2008 Third Quarter Results
Date:11/4/2008

026 18,917 (20,059) 2,829 637,651

Amortization

- intellec-

tual

property 90,375 90,375 271,125 271,125 3,343,875

Amortization

- property

and

equipment 11,853 10,197 35,233 30,061 483,630

-------------------------------------------------------------------------

4,239,325 4,105,677 13,242,679 12,780,615 103,831,693

-------------------------------------------------------------------------

Loss

before

the

follow-

ing: 4,239,325 4,105,677 13,242,679 12,780,615 103,521,693

Interest

income (98,493) (319,221) (452,944) (946,826) (6,467,693)

Gain on

sale of

BCY

LifeSciences

Inc. - - - - (299,403)

Loss on

sale of

Transition

Therapeutics

Inc. - - - - 2,156,685

-------------------------------------------------------------------------

Loss before

income

taxes 4,140,832 3,786,456 12,789,735 11,833,789 98,911,282

Future

income

tax

recovery - - - - (1,115,000)

-------------------------------------------------------------------------

Net loss

and

compre-

hensive

loss for

the

period 4,140,832 3,786,456 12,789,735 11,833,789 97,796,282

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Basic and

diluted

loss per

share 0.10 0.09 0.31 0.29

------------------------------------------------------------

----------------------------------------
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Tooth decay is an epidemic in American ... the disease. The World Health Organization says that worldwide, ... have cavities. What are the long-term effects of this transmissible ... connection between the oral bacterial imbalance and serious systemic issues ... yet it is also 100% preventable? Answer: there has been ...
(Date:5/16/2013)... 16, 2013 Oven Industries, Inc. has ... and temperature sensors since 1964. Expertly designed, ... industrial control system applications. As one of ... a generic, control loop feedback system, which helps minimize ... to adjust a systematic process, using a control element, ...
(Date:5/16/2013)... Cambridge Healthtech Institute will host its fifth annual ... Renaissance Waterfront Hotel in Boston, MA. The ten ... the current strategies and innovations for optimizing bioprocesses while ... the field will reveal how their work has resulted ... and efficiency. , “In this age of rapid innovation, ...
(Date:5/16/2013)... , May 16, 2013  The registration deadline ... Bioscience Financial Officers (ABFO) 2013 National Conference, the premier ... held May 28-31 at the Hilton San Diego Bayfront. ... on this year,s conference and want to make sure ... attend," said Brandi Roberts , Chief ...
Breaking Biology Technology:Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3New PID Temperature Controllers Announced by Oven Industries Inc. 2The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4
... FRANCISCO, Calif., Feb. 27 Anesiva,Inc. (Nasdaq: ANSV ... executive officer, will present at the Susquehanna Financial Group,SIGnificant ... on,March 5, 2008 at 2:30 pm EDT., To ... log on,to http://www.anesiva.com, go to the Investors ...
... proprietary technology to generate antibodies against ... novel research targets provided by Sigma-Aldrich, ... (Nasdaq: SIAL ) and MorphoSys AG (Frankfurt ... a,collaboration agreement to design, produce and distribute unique,recombinant ...
... Announced Today the Purchase Agreement Entered Into Between Genmab, ... Acquire PDL,s Manufacturing ... has Received Antitrust Clearance, COPENHAGEN, February 26 ... entered into between Genmab and,PDL BioPharma, Inc. under which ...
Cached Biology Technology:Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies 2Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies 3Purchase Agreement for Antibody Manufacturing Facility Receives Antitrust Clearance 2
(Date:5/17/2013)... noise of the South, but the night belongs to the ... heavy from the humidity and the sounds of wildlife. ... frogs, toads and salamanders, is the center of amphibian biodiversity ... the auditorium for their symphonic choruses, the scientists of the ... have front-row seats. , Amphibians, which rely on ...
(Date:5/17/2013)... of proteins in the brain responsible for protecting nerve ... could increase cell survival. , The discovery, made by ... in the EMBO journal with additional comment ... for stroke and other brain diseases. , The research ... a protein, known as SUMO, responsible for controlling the ...
(Date:5/17/2013)... Dartmouth College study finds human-caused climate change may ... lizards, contradicting a host of recent studies that ... planet. , The findings, which appear in the ... hope for survival of a creature thought to ... that tropical cold-blooded animals, especially forest lizards, will ...
Breaking Biology News(10 mins):Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4SUMO wrestling cells reveal new protective mechanism target for stroke 2Climate change may have little impact on tropical lizards 2
... In the year since their 2008 preliminary ranking, Cell Press ... Microbe saw their Impact Factors surge, according to new data ... In the report released June 17, Cell Stem Cell ,s ... journal,s previous score. Cell Host and Microbe ranks 13.021 ...
... Two researchers from the University of Santiago de Compostela ... antisocial behaviour. The results show that the principal goal ... leave home. The most antisocial among them place greater ... teenagers place most importance on are to do with ...
... the University of Leicester may identify reasons underlying an ... In her doctoral study, Cardiovascular Sciences student Lisa ... predominance of AAA, with a particular emphasis on genetic ... will be showcased at the University of Leicester,s Festival ...
Cached Biology News:New 2009 Impact Factors soar for newest Cell Press journals 2Teenagers want to finish their studies and leave home 2Increased likelihood of male death from disease 2
Mouse monoclonal antibody raised against a partial recombinant ST3GAL2. NCBI Entrez Gene ID = ST3GAL2...
... derivative for high-yield protein expression ... from a high-yielding clone of Sf9 cells. ... Insect Cell Medium, these cells are recommended ... either baculovirus infection or transfection of appropriate ...
Mouse monoclonal antibody raised against a partial recombinant VRK2. NCBI Entrez Gene ID = VRK2...
Mouse monoclonal antibody raised against a full length recombinant SCGB3A2. NCBI Entrez Gene ID = SCGB3A2...
Biology Products: